Tatva Chintan Pharma Chem reports consolidated Q2 FY26 PAT at Rs. 9.91 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025

Indraprastha Medical Corporation posts consolidated Q2 FY26 PAT at Rs. 49.46 Cr

Indraprastha Medical Corporation has reported total income of Rs. 388.40 crore during the period ended September 30, 2025

MedPlus Health Services posts consolidated Q2 FY26 PAT at Rs. 55.50 Cr

Medplus Health Services has reported total income of Rs. 1,696.79 crore during the period ended September 30, 2025

Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion

Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter

Merck’s Capvaxive shows strong momentum amid industry vaccine decline

Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success

ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia

FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis